The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | How can PRMT5 inhibitors make an impact on the NSCLC treatment landscape?
Robert Hsu, MD, University of Southern California, Los Angeles, CA, comments on the potential of PRMT5 inhibitors to improve survival outcomes by suppressing PRMT5 expression in non-small cell lung cancer (NSCLC), and highlights the importance of agents that can engage and boost the immune system to address disparate outcomes. These approaches could contribute to better treatment strategies in this setting. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so again, I think the PRMT5 inhibitors, you know, in terms of which could suppress the PRMT5, you know, expression that I think is a contributing factor to worse survival outcomes. And then I think these agents that could engage, you know, parts, you know, more parts of the immune system or boost the immune system stronger could help improve the disparate outcomes that we’re seeing...
Yeah, so again, I think the PRMT5 inhibitors, you know, in terms of which could suppress the PRMT5, you know, expression that I think is a contributing factor to worse survival outcomes. And then I think these agents that could engage, you know, parts, you know, more parts of the immune system or boost the immune system stronger could help improve the disparate outcomes that we’re seeing.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
